

ORIGINAL RESEARCH

The use of microspirometry in detecting lowered FEV₁ values in current or former cigarette smokersPaula Ryttilä^a, Timo Helin^a, *Vuokko Kinnula^b^a Division of Allergology, Helsinki University Central Hospital, Helsinki, Finland^b Department of Medicine, Division of Pulmonary Medicine, University of Helsinki, Helsinki, Finland

Received 11th January 2008; resubmitted 12th March 2008; revised version received 17th April 2008; accepted 9th July 2008; online 2nd October 2008

Abstract

Aims: COPD is an underdiagnosed disease. This study was undertaken to assess the value of microspirometry in detecting reduced FEV₁ values in cigarette smokers i.e. subjects at high risk for COPD.

Methods: A total of 611 smokers or ex-smokers with a smoking history >20 years and no previously-diagnosed lung disease were recruited (389 male, age 27-83 years, mean age 56 years, mean smoking history 35 pack years, 19% ex-smokers).

Results: An FEV₁ < 80% predicted on microspirometry was found in 44.6% of cases. The mean FEV₁ was 2.8 litres (80.6% predicted, range 26-121%). This correlated well with values obtained from full spirometry (R=0.965, p<0.0001). Detailed questionnaire responses revealed that almost half of the subjects (48.2%) reported chronic cough and sputum production and 39.8% reported breathlessness during exercise.

Conclusions: Microspirometry finds a considerable number of smokers or ex-smokers with reduced FEV₁ values. Microspirometry is quick to perform. All smokers with reduced microspirometry FEV₁ values would benefit from smoking cessation, and all patients with reduced FEV₁ values need to be considered for full spirometry to confirm if they actually have COPD.

© 2008 General Practice Airways Group. All rights reserved.

P Ryttilä, et al. *Prim Care Resp J* 2008; 17(4): 232-237.

doi:10.3132/pcrj.2008.00058

Keywords COPD, screening, primary care, general practice, microspirometry, spirometry

See linked Discussion paper by Enright on page 238

Introduction

The prevalence of chronic obstructive pulmonary disease (COPD) is increasing worldwide, but the disease is underdiagnosed.^{1,2} Spirometry can be very useful in identifying new undiagnosed COPD cases.³⁻⁸ However, since there is no medication which can slow the progression of COPD,⁹ the only way to affect the prognosis and control the current COPD epidemic is early detection of the disease combined with effective anti-smoking counselling and smoking cessation.¹⁰⁻¹³

There are several problems with conducting spirometry in primary care – for example, the difficulty of implementing spirometry as a routine procedure in the community, and the interpretation of spirometric results.^{14,15} In Finland, doctors

and nurses in all health centres have participated in the national asthma and COPD programmes which include the teaching of spirometry. Education of general practitioners (GPs) and nurses who perform spirometric tests in the primary care setting has been shown to be beneficial, but there are contradictory results.^{4,14-19} Once patients are informed of their results, full spirometry may lead to significant smoking quit rates especially in patients shown to have airway obstruction, but not all studies have reported such favourable outcomes.²⁰⁻²³ In addition, conducting full spirometry in primary care is costly, and it requires time, expertise and extensive training. Recent guidelines do not suggest using spirometry in order to screen for COPD.²⁴

An alternative method for the preliminary assessment of lung function values and the provisional diagnosis of COPD in primary care is microspirometry. Hand-held office spirometers

* **Corresponding author:** Professor Vuokko Kinnula, Department of Medicine, Division of Pulmonary Medicine, University of Helsinki, PO Box 22, Haartmaninkatu 4, Helsinki, FI-00014, Finland. Tel: +358 9 4717 2255 Fax: +358 9 4717 6107 E-mail: vuokko.kinnula@helsinki.fi

have already been studied in general practice.²⁵ Microspirometry is easy to perform in daily practice, and special focus can be directed to smoking cessation in the same setting. If abnormal values are obtained by microspirometry, full spirometry with bronchodilatation testing can then be performed by an experienced lung function technician either in the health care centre or the hospital.

This study was undertaken to assess the potential value of microspirometry in screening for reduced forced expiratory volume in one second (FEV₁) values – i.e. possible new COPD cases – in primary health care.

Methods

This was a cross-sectional study. Inclusion criteria were: smokers or ex-smokers with a smoking history of 20 pack years or more; no previously diagnosed lung disease; and no respiratory infection in the four weeks before the study. Subjects were recruited by 100 physicians from 23 Finnish health care centres (four or five health centres from each of the five University Hospital Districts in the country) from June 2005 to March 2006. Patients who had previously been treated with inhaled medications were excluded. A careful clinical history was obtained to exclude any patients with a previous diagnosis of asthma or COPD. The study protocol recommended smoking cessation, and health care centres offered organised smoking cessation courses for each subject.

Primary health care physicians who recruited the subjects enquired about chronic respiratory symptoms at rest, during exercise, and during the night. The following symptoms were asked about: prolonged cough; shortness of breath; breathlessness on exertion; and any breathing symptoms at night.

Three microspirometry values (using the One flow tester screen manufactured by Clement Clarke International Ltd, Edinburgh Way, Harlow, Essex CM20 2TT, England) were obtained according to the manufacturer's instructions. All physicians were trained to use the microspirometer before the start of the study, and microspirometers were provided for the whole study period. Training was given by an experienced chest physician.

Pilot testing on 32 subjects with normal lung function parameters recruited from a pulmonary consultant outpatient clinic assessed the correlation between FEV₁ values obtained from microspirometry and those obtained by full spirometry (Spiostar DX Spi-rometer M921, program used Software 1.5.2, manufactured by Medikro Ltd, Kuopio, Finland). In the pilot study, there was excellent correlation between the values obtained by microspirometry and full spirometry ($r=0.965$, $p<0.0001$). In the current study, subjects who had an FEV₁ < 80% predicted were advised to undergo full spirometry with bronchodilatation testing. However, only a subset of investigators (26 different physicians in 15 health care centres)

participated in a sub-study collecting data for full spirometry according to international guidelines ($n=50$).²⁶ The microspirometry values were correlated with values obtained from full spirometry. The percent (%) predicted FEV₁ values are based on Finnish reference values described in more detail by Viljanen.²⁷ These same reference values are used in all lung function laboratories in Finland and they specifically reflect the Finnish population.

All statistical analyses were done using SAS® System for Windows, version 8.2 (SAS Institute Inc., Cary, NC, USA). A two-sided p-value less than 0.05 was considered to be statistically significant. Pearson's correlation coefficients were calculated and compared to zero using t-distribution. Linear regression modelling was used to estimate the FEV₁ (%) as a function of age, gender, the presence of the COPD symptoms, and pack years. Bland-Altman plot was used to describe the agreement between microspirometry and full spirometry FEV₁ values.

This study was approved by the Ethics Committee of Helsinki University Hospital with written consent being obtained from every subject.

Results

A total of 611 smokers or ex-smokers were recruited; 389 were male (64.2%) and 103 (19.0%) were ex-smokers. Patient characteristics are shown in Table 1. The mean age

Table 1. Patient characteristics.

	Age (years)	Height (cm)	Weight (kg)	BMI (kg/m ²)	Age when started smoking	Pack years
Mean	55.7	171.8	79.9	26.9	18.1	35.1
5% percentile	39	157	53	19.8	12	20
95% percentile	73	186	114	36.9	28	59

Figure 1. Distribution of FEV₁ values (% of predicted).





Figure 2A and 2B. Correlation between FEV₁ (% predicted) versus age (years) and pack years. Pearson's correlation coefficient (r) and p-value comparing the correlation coefficient to zero are shown in the figure.



was 56 years and mean smoking history was 35 pack years. The mean (range) FEV₁ measured by microspirometry was 2.8 (0.8-6.0) litres which is 80.6% (26-121%) of predicted values (Finnish reference values).²⁷ An abnormal FEV₁ (below 80% predicted) was found in 270 smokers (44.6%).

The frequency distribution of FEV₁ values (% predicted) can be seen in Figure 1. Of the subjects who had an FEV₁ < 80% predicted, 50% had an FEV₁ between 70-80% predicted, 40% an FEV₁ between 50-70% predicted, and 10% an FEV₁ < 50% predicted. In all, 294 subjects (48.2%) reported chronic cough and sputum production, 231 subjects (37.9%) complained of shortness of breath, 242 subjects (39.8%) exhibited breathlessness with exercise, and 107 (17.6%) experienced symptoms at night.

There was a significant negative correlation between age and FEV₁ % predicted ($r=-0.23$, $p<0.001$, Figure 2a) and between pack years and FEV₁ % predicted ($r=-0.21$, $p<0.001$, Figure 2b). The linear regression analysis showed that higher age and presence of breathlessness on exercise, shortness of breath and chronic cough were explanatory factors for lowered FEV₁ values. Furthermore, as expected, female subjects had lower FEV₁ values than male subjects (Table 2).

In addition to the pilot study on healthy subjects with normal lung function values, a sub-set of patients ($n=50$) with FEV₁ < 80% predicted had full spirometry conducted after microspirometry. A very good correlation was again found between the FEV₁ values and the two measurements ($r=0.87$, $p<0.001$, Figure 3) even though microspirometry in general was found to be associated with lower values than full spirometry. Of the 50 subjects who had an FEV₁/forced vital capacity (FVC) ratio below 88% predicted – the ratio used normally in Finland.^{27,28}

Discussion


Our study shows that primary health care microspirometry

Table 2. Linear regression analysis of FEV₁ (% of predicted).

Explanatory factor	Estimate of regression coefficient	P-value*
Age (years)	-0.378	<0.001
Gender (male vs. female)	4.803	<0.001
Breathlessness in exercise (yes vs.no)	-4.458	0.002
Shortness of breath (yes vs. no)	-4.462	0.002
Chronic cough, sputum production (yes vs. no)	-3.210	0.018
Pack years	-0.081	0.113
Symptoms at night (yes vs. no)	-0.754	0.672

* P-value is comparing the estimate of regression coefficient to zero.

Figure 3. Bland-Altman plot comparing FEV₁ (L) measured using microspirometry with office spirometry. The office spirometry was performed after microspirometry in a subset of 50 patients.



screening of smokers or ex-smokers with a smoking history > 20 pack years can identify a large group of subjects with low FEV₁ values. Even though no bronchodilator reversibility testing had been performed, the FEV₁ values obtained from microspirometry correlated well with values obtained from full spirometry.

Smokers with reduced lung function tended to be older than smokers with better lung function and there was a significant negative correlation between FEV₁ % predicted and age. Similarly, there was a negative correlation between lung function and smoking history. The risk of developing COPD increases with age and smoking history,²⁹ and it has been proposed that screening for COPD should be limited to older age groups.³⁰ However, in a recent European study, a high number of younger smokers (aged 20 to 40 years) had COPD, and even mild disease was associated with more extensive use of health care resources.³¹ In the current study there were several cases of low FEV₁ among younger smokers. Many Europeans smoke at an even younger age³² and therefore it is not uncommon to find COPD in young smokers; they tend to have less nicotine dependence and a higher potential for successful quitting.²⁰ Therefore, based on these findings, screening for COPD and especially smoking cessation efforts should not be restricted to older smokers. Furthermore, normal lung function can also be used as a motivational tool for quitting: it is never too late to stop smoking ...

It is difficult to determine the target group of smokers who should be directed to full spirometry since many smokers are symptom-free, and there may be symptoms without the presence of airway obstruction. Our study showed that smokers with reduced lung function experience more symptoms than smokers with normal lung function – as would be expected – and that symptomatic smokers have lower FEV₁ values than non-symptomatic smokers. In a Dutch study,³³ spirometry needed to be conducted in four patients with prolonged cough to find one at-risk patient with an FEV₁ < 80% predicted; however, in their sub-group of symptomatic smokers over 60 years old, obstruction was found in 45%. In another study from Poland, 31% of smokers with more than 10 years' smoking history (over the age of 40 years) exhibited obstruction whereas only 8.3% of smokers < 40 years old and with a smoking history < 10 pack years had obstruction.⁶ The latter percentage was less than in older never-smokers.

It is known that symptoms alone are poor indicators of COPD and that spirometry is mandatory if one wishes to detect COPD.¹³ To avoid these caveats, the exact target group for COPD screening should perhaps not be limited only to symptomatic smokers. Most new cases found by screening spirometry represent mild/moderate disease, and often do not require any therapy. It is, however, of the utmost importance

that all smokers, regardless of how long they have smoked, should be given appropriate advice and help to quit smoking.

All current guidelines state that COPD diagnosis and staging requires spirometry and a bronchodilatation test.^{9,34} However, there is controversy about the use of spirometry in COPD case-finding.^{35,36} Recent recommendations commissioned by the United States Agency for Health Research and Quality³⁷ and the USA Preventive Services Task Force (USPSTF)²⁴ found little if any justification for conducting spirometry in primary care for the screening of COPD. These conclusions were based on the cost and poor prognostic value of spirometry to predict future respiratory impairment, and on the inability of current medical therapies available for mild COPD to reduce disease progression and exacerbation rates. These recommendations did not include any studies on microspirometry. There are data showing that detection of bronchial obstruction by spirometry can lead to both smoking cessation and to a reduction in the numbers of cigarettes smoked per day²⁰⁻²² even though opposite results have been reported as well.²³ Recent studies from Poland^{20,21} suggest that simple smoking cessation advice combined with spirometry can result in good one-year cessation rates of 16.3%, especially in those subjects with airway obstruction.²⁰ In this Polish study, the validated smoking cessation rate in those with *normal* spirometric parameters was relatively good (12.0%). Similar findings were found in a recent Swedish study where annual spirometry and brief cessation advice by a nurse showed high smoking cessation rates (25-29%) in smokers with COPD.²² These results are also in agreement with an older study in which quit rates improved to 22% when spirometry was combined with education and nicotine replacement therapy.³⁸ Overall, it appears that spirometry combined with an efficient antismoking campaign can improve smoking cessation – and therefore microspirometry may be a practical way to start this screening.

Microspirometry is quick to perform, does not take longer than measuring blood pressure, and the measurements can also be performed by a clinical nurse specialist in the community.³⁹ This is no more difficult than using peak expiratory flow (PEF) meters, with which there has been excellent experience in Finland within the National Asthma and COPD Programmes.^{16,18} Peak flow values, however, have several weaknesses compared to FEV₁ measurements, one of which is their effort dependence.

One important aspect about screening is whether it is cost effective.^{19,40} Full spirometry generally requires another visit to a lung function laboratory, while microspirometry can be successfully performed during the visit to the GP or experienced nurse with a low cost device (around 110€) – as compared to spirometry which requires more personnel. Moreover, many primary care facilities have a shortage of qualified staff and limited financial resources. Even though the values obtained by

full spirometry and microspirometry correlated very well, values obtained by microspirometry were generally lower than those obtained by full spirometry. The optimal cut-off value obtained by the ROC analyses (not shown) in order to distinguish between normal values was below 70% for microspirometry instead of 80% for full spirometry.

One limitation of our study was that we did not systemically determine the impact of microspirometry screening on patient follow-up. Only in a sub-set of patients was full spirometry conducted in order to assess reproducibility. Nevertheless, microspirometry measurements were accurate and the correlation with full spirometry was excellent both in the pilot study in normal controls and smokers, and in subjects with reduced FEV₁ values, as has been shown previously.⁴¹ Our impression is that the awareness of COPD among the primary care physicians involved was greatly improved. The patients were directed to smoking cessation programs, but this cross-sectional study was not designed to quantify these parameters. Our study was done in a relatively short period of time over nine months. Previous data has shown that unless there is continuous re-enforcement by using spirometry for the screening of smokers, the enthusiasm fades.¹⁴ This emphasises the importance of national programmes for COPD and on-going education.¹⁷ Other potential diagnoses for symptomatic smokers with a low FEV₁ are restrictive lung diseases and asthma. They should be excluded by means of a chest X-ray, spirometry and bronchodilatation test and PEF follow-up measurements. It can also be argued that subjects with normal FEV₁ values might have a reduced FEV₁/FVC ratio and risk of developing COPD. This is certainly possible, but resources in order to perform full spirometry for all smokers are often limited in primary care.

In conclusion, our study has shown that it is feasible to screen for abnormally low FEV₁ values – i.e. probable COPD – with microspirometry in primary health care, and that the accuracy of measurements when compared to full spirometry is excellent. Microspirometry identifies a large population of smokers or ex-smokers with lowered FEV₁ values who have no previous diagnosis of lung disease. Its use is not only feasible but also cost-effective, and the availability of this technique improves COPD awareness among both primary health care physicians and smokers. Individuals with abnormal microspirometry values need to be investigated further by full spirometry and reversibility testing. In addition, all smokers with either normal or abnormal FEV₁ values shown on microspirometry would benefit from smoking cessation.

Acknowledgements

The study was partly supported by funding from the Helsinki University Hospital (EVO) and Finnish Antituberculosis Association Foundations. The authors would like to thank all the primary care physicians who recruited patients: Harju T, Laatikainen A, Böök A, Taivainen H, Salminen A, RiihÄ A, Rosengren L, Huopaniemi L, Kaskimies-Bärlund L,

Korolainen V, Kroutskih V, Pohjola E, Olkonieni J, Krohn M, Sandström A, Eloranta A, Kempainen R, Lahtinen T, Salminen T, Kobler K, Lohva J, Vesselin G, Huopaniemi L, Knuttila L, Jääskeläinen E, Huvinen E, Maaninka R, Nykänen H, Kempainen M, Rouhe E, Lampio M, Miilunpalo E, Keihäskoski M, Haapasalo E, Tuominen S, Sundell K, Luostarinen J, Borman R, Vastamäki U, Rinne H, Valovirta R, Levola J, Westergård K, Santavirta M, Raunio M, Nordqvist H, Karhilahti P, Niemi K, Matiskainen P, Karjalainen J, Vasama J, Lietzen K, Ahonen K, Sali K, Tervo J, Rajala A, Ratalahti H, Kanto M, Lopenon A, Aaltonen S-P, Häggblom J-O, Martikainen J, Halme J, Heinimäki E, Ruohotie V, Lehmus K, Alenius H, Räsänen A, Kangasrääsiö P, Kokko R, Ylinen T, Kettunen R, Huovinen A, Moilanen O, Nevalainen V, Pohjolainen P, Ritala A, Vuori R, Eräpuro K, Iloa H, Piirainen K, Suhonen M, Rytönen R, Räsänen R, Hyvärinen H, Haapaniemi J, Simojoki I, Karjalainen K, Rahko J, Kuula S, Piuva J, Mäntymaa J, Hiltunen A, Linna A, Linna A, Röning K, Nasim M, Nenola L, Mäkinen H, Taulavuori T, Mella S, Loukusa-Nieminen T, Mäntymaa M, Hakala E, Romppainen M.

We thank Mika Leinonen from 4Pharma AB for helping with the statistical analysis. We are grateful to Jouni Keränen M. Sci from Boehringer Ingelheim for his extensive help in performing this study.

Conflict of interest statement and funding declaration

This study was sponsored by Boehringer Ingelheim and Pfizer. Timo Helin is employed by Boehringer Ingelheim.

References

- Lindberg A, Jonsson AC, Ronmark E, Lundgren R, Larsson LG, Lundback B. Prevalence of chronic obstructive pulmonary disease according to BTS, ERS, GOLD and ATS criteria in relation to doctor's diagnosis, symptoms, age, gender, and smoking habits. *Respiration* 2005;**72**(5):471-9.
- Rabe KF, Hurd S, Anzueto A *et al.* Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med* 2007;**176**(6):532-55.
- Stratelis G, Jakobsson P, Molstad S, Zetterstrom O. Early detection of COPD in primary care: screening by invitation of smokers aged 40 to 55 years. *Br J Gen Pract* 2004;**54**(500):201-06.
- Griffiths C, Feder G, Wedzicha J, Foster G, Livingstone A, Marlowe GS. Feasibility of spirometry and reversibility testing for the identification of patients with chronic obstructive pulmonary disease on asthma registers in general practice. *Respir Med* 1999;**93**(12):903-08.
- Enright P. Does screening for COPD by primary care physicians have the potential to cause more harm than good? *Chest* 2006;**129**(4):833-5.
- Zielinski J, Bednarek M. Early detection of COPD in a high-risk population using spirometric screening. *Chest* 2001;**119**(3):731-6.
- Zielinski J, Bednarek M, Gorecka D, *et al.* Increasing COPD awareness. *Eur Respir J* 2006;**27**(4):833-52.
- Walker PP, Mitchell P, Diamantea F, Warburton CJ, Davies L. Effect of primary-care spirometry on the diagnosis and management of COPD. *Eur Respir J* 2006;**28**(5):945-52.
- Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. *Am J Respir Crit Care Med* 2001;**163**(5):1256-76.
- Xu X, Dockery DW, Ware JH, Speizer FE, Ferris BG, Jr. Effects of cigarette smoking on rate of loss of pulmonary function in adults: a longitudinal assessment. *Am Rev Respir Dis* 1992;**146**(5 Pt 1):1345-8.
- Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. *Am J Respir Crit Care Med* 2002;**166**(5):675-9.
- Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel MK, Jamerson B. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. *Lancet* 2001;**357**(9268):1571-5.
- Buffels J, Degryse J, Heyrman J, Decramer M. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study.

- Chest* 2004;**125**(4):1394-9.
14. Lusuardi M, De BF, Paggiaro P, Sanguinetti CM, Brazzola G, Ferri P, Donner CF. A randomized controlled trial on office spirometry in asthma and COPD in standard general practice: data from spirometry in Asthma and COPD: a comparative evaluation Italian study. *Chest* 2006;**129**(4):844-52.
 15. Schermer TR, Jacobs JE, Chavannes NH, Hartman J, Folgering HT, Bottema BJ, van WC. Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). *Thorax* 2003;**58**(10):861-6.
 16. Haahtela T, Tuomisto LE, Pietinalho A, et al. A 10 year asthma programme in Finland: major change for the better. *Thorax* 2006;**61**(8):663-70.
 17. Laitinen LA, Koskela K. Chronic bronchitis and chronic obstructive pulmonary disease: Finnish National Guidelines for Prevention and Treatment 1998-2007. *Respir Med* 1999;**93**(5):297-332.
 18. Pietinalho A, Kinnula VL, Sovijarvi AR, et al. Chronic bronchitis and chronic obstructive pulmonary disease. The Finnish Action Programme, interim report. *Respir Med* 2007;**101**(7):1419-25.
 19. van den Boom G., van Schayck CP, van Mollen MP, et al. Active detection of chronic obstructive pulmonary disease and asthma in the general population. Results and economic consequences of the DIMCA program. *Am J Respir Crit Care Med* 1998;**158**(6):1730-8.
 20. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. *Thorax* 2006;**61**(10):869-73.
 21. Gorecka D, Bednarek M, Nowinski A, Puscinska E, Goljan-Geremek A, Zielinski J. Diagnosis of airflow limitation combined with smoking cessation advice increases stop-smoking rate. *Chest* 2003;**123**(6):1916-23.
 22. Stratelis G, Molstad S, Jakobsson P, Zetterstrom O. The impact of repeated spirometry and smoking cessation advice on smokers with mild COPD. *Scand J Prim Health Care* 2006;**24**(3):133-9.
 23. Buffels J, Degryse J, Decramer M, Heyrman J. Spirometry and smoking cessation advice in general practice: a randomised clinical trial. *Respir Med* 2006;**100**(11):2012-17.
 24. Screening for chronic obstructive pulmonary disease using spirometry: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2008;**148**(7):529-34.
 25. Derom E, van WC, Liistro G, et al. Primary care spirometry. *Eur Respir J* 2008;**31**(1):197-203.
 26. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. *Eur Respir J* 2005;**26**(2):319-38.
 27. Viljanen AA, Halttunen PK, Kreis KE, Viljanen BC. Spirometric studies in non-smoking, healthy adults. *Scand J Clin Lab Invest Suppl* 1982;**159**:5-20.
 28. Siafakas NM, Vermeire P, Pride NB, et al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. *Eur Respir J* 1995;**8**(8):1398-420.
 29. Kotaniemi J-T, Sovijarvi A, Lundback B. Chronic Obstructive Pulmonary Disease in Finland: prevalence and risk factors. *Journal of COPD* 2005;**3**:331-9.
 30. Ferguson GT, Enright PL, Buist AS, Higgins MW. Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program. *Respir Care* 2000;**45**(5):513-30.
 31. De Marco R., Accordini S, Cerveri I, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. *Thorax* 2004;**59**(2):120-5.
 32. Lindstrom M, Kotaniemi J, Jonsson E, Lundback B. Smoking, respiratory symptoms, and diseases: a comparative study between northern Sweden and northern Finland: report from the FinEsS study. *Chest* 2001;**119**(3):852-61.
 33. van Schayck CP, Chavannes NH. Detection of asthma and chronic obstructive pulmonary disease in primary care. *Eur Respir J Suppl* 2003;**39**:16s-22s.
 34. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. *Eur Respir J* 2004;**23**(6):932-46.
 35. Boushey H, Enright P, Samet J. Spirometry for chronic obstructive pulmonary disease case finding in primary care? *Am J Respir Crit Care Med* 2005;**172**(12):1481-2.
 36. Mannino DM. Spirometric screening: Does it work? *Thorax* 2006;**61**(10):834-5.
 37. Wilt TJ, Niewoehner D, Kim C, et al. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). *Evid Rep Technol Assess (Summ)* 2005;(121):1-7.
 38. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. *JAMA* 1994;**272**(19):1497-505.
 39. DeJong SR, Veltman RH. The effectiveness of a CNS-led community-based COPD screening and intervention program. *Clin Nurse Spec* 2004;**18**(2):72-9.
 40. Cromwell J, Bartosch WJ, Fiore MC, Hasselblad V, Baker T. Cost-effectiveness of the clinical practice recommendations in the AHCPR guideline for smoking cessation. Agency for Health Care Policy and Research. *JAMA* 1997;**278**(21):1759-66.
 41. Malmberg LP, Hedman J, Sovijarvi AR. Accuracy and repeatability of a pocket turbine spirometer: comparison with a rolling seal flow-volume spirometer. *Clin Physiol* 1993;**13**(1):89-98.

Available online at <http://www.thepcrj.org>